Antibiotic resistance - Bacteria fight back;Prevelika uporaba antibiotika - Bakterije uzvraćaju udarac

Acta Medica Croatica

Volumn 58, Issue 4, 2004, Pages 245-250

  Tambic Andrasevic, Arjana ^a  

^a Croatia   (Croatia)

Author keywords

Antibiotics; Community acquired infections; Nosocomial infections; Resistance; Surveillance

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE; PENICILLIN G; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CORRELATION ANALYSIS; CROATIA; EPIDEMIC; EUROPE; FERMENTATION; GENE MUTATION; GENETIC CODE; GRAM NEGATIVE BACTERIUM; HEALTH SURVEY; HUMAN; INFECTION SENSITIVITY; MOLECULAR EVOLUTION; NETHERLANDS; NONHUMAN; PLANT; PRESSURE GRADIENT; PREVALENCE; PSEUDOMONAS AERUGINOSA; PUBLIC HEALTH; REVIEW; SCANDINAVIA; SOIL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEM ANALYSIS; TECHNIQUE;

COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 12344285844     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Low DE, Scheld WM. Strategies for stemming the tide of antimicrobial resistance. JAMA 1988; 279: 394-5.
2. Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989; 320: 1188-96.
3. Bradley SF. Methicillin-resistant Staphylococcus aureus infection. Infect Dis 1992; 8: 853-68.
4. Voss A i sur. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50-5.
5. Boyce JM. Methicillin-resistant Staphylococcus aureus: a continuing infection control challenge. Eur J Clin Microbiol Infect Dis 1994; 13: 45-9.
6. European Committee for Antimicrobial Susceptibility Testing (EUCAST). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000; 6: 503-8.
7. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Aproved standard - sixth edition. Pennsylvania, 2003; document M7-A6.
8. BSAC. A guide to sensitivity testing. London: Academic Press Ltd, 1991.
9. SRGA and SRGA - M. Susceptibility testing. SRGA, 2000.
10. Tenover FC, McGowan JE. Reasons for the emergence of antibiotic resistance. Am J Med Sci 1996; 311: 9-16.
11. Struelens M. The problem of resistance. U: Finch RG, Greenwood D, Norrby SR, Whitley RJ, ur. Antibiotic and Chemotherapy, 8th ed. Philadelphia: Churchill Livingstone, 2003, 25-47.
12. Lewis K. Riddle of biofilm resistance. Antimicrob Agent Chemother 2001; 45: 999-1007.
13. Harwell JI, Brown RB. The drug-resistant pneumococcus. Clinical relevance, therapy, and prevention. Chest 2000; 117: 530-41.
14. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375-82.
15. Henderson DK, Levy SB. Resistant organisms: Global impact on continuum of care. International Congress and Symposium Series 220. New York: Royal Society of Medicine, 1997.
16. Greenwood D. Preserving the miracle of antibiotics. Lancet 1995; 345: 1371.
17. Schmidt LH, Sesler CL. Development of resistance to penicillin by pneumococci. Proc Soc Exp Biol Med 1943; 52: 353-7.
18. Hansman D, Bullen MM. A resistant pneumococcus (letter). Lancet 1967; 2: 264-5.
19. Appelbaum PC, Bhamjee A, Scragg JN, Hallett AF, Bowen AJ, Cooper RC. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977; 2: 995-7.
20. Jacobs MR, Koornhof HJ. Robins-Browne RM i sur. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299: 735-10.
21. Doern GV, Brueggemann AB, Blocker M i sur. Clonal relationships among high-level penicillin resistant Streptococcus pneumoniae in the United States. Clin Infect Dis 1991; 164: 302-6.
22. Munoz R, Coffey TJ, Daniels M i sur. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 1991; 164: 302-6.
23. Odbor za praćenje rezistencije bakterija na antibiotike. Osjetljivost i rezistencija bakterija na antibiotike u RH u 2002. g. Zagreb: AMZH, 2003.
24. Leclerq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267-72.
25. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995; 39: 577-85.
26. Sutcliffe J, Tait-Karmadt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817-24.
27. Steigbigel NH. Macrolides and Clindamycin. U: Mandell GL, Bennett JE, Dolin R, ur. Principles and Practice of Infectious Diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000; 366-82.
28. Nagai K, Appelbaum PC, Davies TA i sur. Susceptibility to telithromycin in 1011 Streptococcus pyogenes isolates from 10 Central and Eastern European countries. Antimicrob Agents Chemother 2002; 46: 546-9.
29. Nagai K, Appelbaum PC, Davies TA i sur. Susceptibilities to telithromycin and six other agents and the prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 Central and Eastern European Countries. Antimicrob Agents Chemother 2002; 46: 371-7.
30. Tait-Kamardat A, Davies T, Jacobs MR i sur. Mutation in 23S rRNA and L4 ribosomal protein account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000; 44: 1894-99.
31. Malbruny B, Nagai K, Coquemont M i sur. Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. J Antimicrob Ther 2002; 49: 935-92.
32. Flemingham D, Gruenberg RN and the Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community acquired lower respiratory tact infections. J Antimicrob Chemother 2000; 45: 191-203.
33. Doern GV, Bruggemann AB, Pierce G, Hogan T, Holley HP, Rauch A. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 2884-6.
34. Phillips I. Beta-lactamase producing, penicillin-resistant gonococcus. Lancet 1976 2: 656-7.
35. Tambic A, Power EGM, Tambić T, Snur I, French GL. Epidemiological analysis of methicillin-resistant Staphylococcus aureus in a Zagreb Trauma Hospital using a randomly amplified polymorphic DNA-typing method. Eur J Clin Microbiol Infect Dis 1999; 18: 335-40.
36. Deplano A, Witte W, van Leeuwen WJ i sur. Clonal dissemination of epidemic methicillin-resistant Staphylococcus aureus in Belgium and neighboring countries. Clin Microbiol Infect 2000; 6: 239-45.
37. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7: 178-82.
38. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710-21.
39. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical stain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
40. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 93: 195-8.
41. CDC. Staphylococcus areus resistant to vancomycin-United States, 2002. MMWR 2002; 51: 565-7.
42. CDC. Public Health Dispatch: Vancomycin-Resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR 2002; 51: 902.
43. World Health Organization. WHO global strategy for containment of antimicrobial resistance. Geneve: WHO, 2001.
44. Tambić Andrašević A, Tambić T, Kalenić S, Janković V. Surveillance for antibiotic resistance in Croatia. Emerg Infect Dis 2002; 8: 14-18.